创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

GU Manyu, YE Bing, GAO Shenghua, ZHAN Peng, LIU Xinyong. Drug Resistance Mechanisms of SARS-CoV-2 Main Protease and Chemical Strategies for Anti-Resistant Drugs[J]. Progress in Pharmaceutical Sciences, 2024, 48(9): 644-660. DOI: 10.20053/j.issn1001-5094.2024.09.002
Citation: GU Manyu, YE Bing, GAO Shenghua, ZHAN Peng, LIU Xinyong. Drug Resistance Mechanisms of SARS-CoV-2 Main Protease and Chemical Strategies for Anti-Resistant Drugs[J]. Progress in Pharmaceutical Sciences, 2024, 48(9): 644-660. DOI: 10.20053/j.issn1001-5094.2024.09.002

Drug Resistance Mechanisms of SARS-CoV-2 Main Protease and Chemical Strategies for Anti-Resistant Drugs

  • The SARS-CoV-2 main protease (Mpro) plays a key role in the viral replication cycle, and is an important target for anti-SARSCoV-2 drugs. However, the rapid mutation of the virus has led to drug resistance with Mpro inhibitors, posing a serious threat to global public health. This article summarizes the resistance mechanisms of SARS-CoV-2 Mpro and explores the strategies for the design of new anti-resistant inhibitors. By analyzing the impact of Mpro resistance mutations on the efficacy of existing inhibitors, we summarized various target structurebased anti-resistance drug design methods such as multi-site occupancy, allosteric site development, and covalent binding, and discussed the utility of PROTAC technology in degrading resistant viral proteins, aiming to provide innovative solutions to the drug resistance problem of SARS-CoV-2 Mpro and some reference for drug screening and development in response to potential future coronavirus pandemics.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return